Drug Profile
IPX 218
Alternative Names: IPX-218Latest Information Update: 15 May 2018
Price :
$50
*
At a glance
- Originator Impax Pharmaceuticals
- Class Antiepileptic drugs
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 07 May 2018 Amneal Pharmaceuticals and Impax Laboratories completed their business combination to form Amneal Pharmaceuticals
- 24 Feb 2016 Discontinued - Phase-II for Epilepsy in USA (unspecified route)
- 01 Aug 2014 IPX 218 is available for licensing as of 01 Aug 2014. http://www.impaxlabs.com/our_company/future_directions